Abstract
A disruptive clinical trial design allowed Drilon and colleagues to demonstrate proof of concept of the potential of PF-07284892 to overcome resistance mechanisms to targeted therapies in the clinic.
Keywords
Combination trials; Cancer
Bibliographic citation
Hernando-Calvo A, Garralda E. Patient Centric Approaches for Phase I Combination Trials Come on Stage. Cancer Discov. 2023 Aug 4;13(8):1762–64.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/10254This item appears in following collections
- HVH - Articles científics [2469]
- VHIO - Articles científics [728]
The following license files are associated with this item: